ArticleBMC biotechnology2026
CyanoConstruct: simple platform for cyanobacterial expression construct assembly and translational tuning.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cyanobacteria as a Photosynthetic Chassis for Metabolic Pathway Engineering with Heterologous Gene Expression.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundDespite the advances in synthetic biology, the construction of efficient and balanced artificial pathways remains challenging and a general bottleneck in bacterial strain development. Although translational tuning can be applied for balancing consecutive catalytic steps at protein expression level, the potential remains underexplored in cyanobacterial engineering. To complement existing modular cloning systems for this purpose the objective here was to simplify the construct assembly procedure to make translational tuning more accessible for expression optimization in cyanobacteria.
resultsThis study describes the design and use of a one-pot DNA construct assembly system (CyanoConstruct) for the generation transformation-ready multi-gene expression plasmids in a single Golden Gate reaction. This approach allows the user to select the ribosome binding site element (RBS) for each target gene, thus serving as a tool for independently modulating the translation efficiency of the individual overexpressed enzymes. For easy adaptation, a custom online tool ( www.cyanoconstruct.com ) guides the sequence design of new compatible parts and the assembly of constructs from user-specified parts in silico. We demonstrate the use of the system by assembling different two-gene and three-gene expression constructs from parts selected specifically for optimal performance in Synechocystis sp PCC 6803; the constructs functioned as intended in vivo and showed different pathway fluxes construed by alternative RBS combinations. The efficiency and specificity of the assembly were shown to be high, enabling the generation of the final expression plasmids from the library parts in one assembly cycle.
conclusionsCyanoConstruct offers a simple strategy for building bacterial operon-based expression constructs, specifically facilitating the use of modular cloning systems for RBS optimization in routine cyanobacterial engineering. With the help of the web-based design tool that also serves as a sequence repository, the part library described in this work (https://www.addgene.org/browse/article/28263931/) can be easily expanded with user-specified sequences. By increasing the throughput for generating pathway variants with different translational patterns, the system is expected to advance the design of more efficient strains with higher flux to the desired end-product, thereby contributing to the development of next-generation biotechnologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.